Inhaled prostaglandin (PG)E 2 has been found to cause bronchodilation in asthmatics, although it does not have bronchodilative effects in normal subjects. The aim of this study was to investigate the levels of PGE 2 in the expired breath condensate of patients with asthma, the possible contribution of smoking habit to its levels and the possible relationship between PGE 2 and the degree of bronchial hyperresponsiveness, as assessed by the provocation dose of histamine causing a 20% fall in forced expiratory volume in one second (FEV1) (PD20).A total of 30 mild asthmatics (15 smokers, all steroid-naive, FEV1 88¡6 (%¡SD)) and 20 healthy control subjects (10 smokers) were studied. Histamine challenge testing was performed in all subjects and the PD20 was determined.The results showed that asthmatic smokers had significantly higher values of PGE 2 compared to asthmatic nonsmokers and control subjects (40¡21 versus 14.5¡4.5 versus 11.7¡3 pg?mL -1 , respectively). Further analysis showed that PGE 2 levels were significantly higher in asthmatic smokers compared to smoker and nonsmoker controls (40¡21 versus 11.6¡2 versus 11.7¡4 pg?mL -1 , respectively). No significant difference was observed between asthmatic nonsmokers and both control smokers and control nonsmokers. No significant correlation was found between PGE 2 levels and PD20 in all groups of asthmatics, irrespective of smoking habit.In conclusion, the elevation of prostaglandin E 2 in the expired breath condensate of patients with asthma is mainly attributed to smoking habit and prostaglandin E 2 levels do not predict the degree of bronchial hyperresponsiveness. Eicosanoids are important inflammatory mediators in asthma. These lipid mediators include leukotrienes, prostaglandins and thromboxanes. Prostaglandin (PG)E 2 is a dominant cyclooxygenase product of airway epithelium and smooth muscle, and is considered to be immunomodulatory and predominantly bronchoprotective [1]. PGE 2 inhibits both exercise-induced bronchoconstriction [2] and allergen-induced early and late asthmatic responses [3], and also prevents aspirin-induced bronchoconstriction in aspirin-sensitive asthma [4]. PGE 2 has also been shown to decrease exhaled nitric oxide [5] and to prevent the induction of inducible NO synthase in certain cell lines [6]. In vitro studies have shown that PGE 2 inhibits many inflammatory events, including mast cell mediator release and eosinophil activation [7].The measurement of markers in the expired breath condensate (EBC) has proven to be a useful noninvasive method for the assessment and monitoring of airway inflammation [8]. EBC is a simple, noninvasive technique for monitoring airway inflammation. It reflects abnormalities in markers obtained bronchoscopically, in sputum and in exhaled air [8]. Measurement of PGE 2 in EBC of asthmatic patients, when compared to normal subjects, has not shown any significant differences [9,10]. However, recent evidence suggests that cigarette smoke stimulates the formation of PGE 2 in airway macrophages [11].Despi...